A Phase 1, Open-Label, Dose-Escalation with Expansion Study of SX-682 in Subjects with Metastatic Melanoma Concurrently Treated with Pembrolizumab

Cancers attract myeloid-derived suppressor cells (MDSCs) that prevent our own immune
responses from destroying the cancer. This study will be the first study to begin to
determine if the newly discovered drug SX-682 can block cancers from attracting MDSCs. This
first study will enroll participants with melanoma, as melanoma cancer has been shown to be
able to attract MDSCs. The study will begin to determine if SX-682 is a safe and effective
treatment of melanoma. It is thought that SX-682 will block MDSCs from going to the cancer,
and thus will allow a patient's own immune system to attack the cancer.

The first participants enrolled in the study will receive for 21 days SX-682 as monotherapy.
After 21 days participants will receive pembrolizumab therapy (an approved immunotherapy for
melanoma) in combination with SX-682 for up to approximately 2 years.

Once the safe dose level of SX-682 in combination with pembrolizumab is determined, the
remaining participants will be enrolled at the highest safe dose level of SX-682, in
combination with pembrolizumab. These participants will receive the combination therapy and
be evaluated in the study for approximately 2 years.

Inclusion Criteria:

1. Written Informed Consent and HIPAA Authorization

1. Subjects must have the nature of the study explained to them.

2. Subjects must be willing and able to comply with scheduled visits, treatment
schedule, laboratory tests, pharmacokinetic collections, and other requirements
of the study.

3. Subjects must provide a signed and dated IRB/IEC approved written informed
consent form (ICF) in accordance with regulatory and institutional guidelines.

4. Subjects must provide a signed and dated Health Insurance Portability and
Accountability Act (HIPAA) authorization.

5. The ICF and HIPAA authorization must be obtained before conducting any procedures
that do not form a part of the subject's normal care.

6. After signing the ICF and HIPAA Authorization, subjects will be evaluated for
study eligibility during the Screening Period (no more than 28 days before study
drug administration) according to the following further inclusion/exclusion
criteria:

2. Target Population

1. Histologically confirmed unresectable Stage III or Stage IV melanoma as per AJCC
staging system. (mucosal melanoma is acceptable).

2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.

3. Prior disease progression on anti-PD1 therapy (i.e., anti-PD1 or anti-PD-L1,
including prior adjuvant). Prior anti-PD1 therapy must have been completed prior
to first dose of SX-682, and all adverse events related to prior therapy have
either returned to baseline or stabilized (other than endocrine toxicity for
which medical replacement therapy is in place).

4. Must have at least measurable non-CNS disease with at least 1 unidimensional
measurable lesion per RECIST v1.1.

5. Pre-treatment tumor tissue (i.e., archived paraffin-embedded) obtained in the
metastatic setting or from an unresectable site of disease must be available for
biomarker analyses. Biopsy should be excisional, incisional punch or core needle.
Fine needle aspirates or other cytology samples are insufficient.

6. Prior radiotherapy must have been completed at least 2 weeks prior to study drug
administration.

7. Screening laboratory values must meet the following criteria and should be
obtained within 14 days prior to first dose:

WBC > 3000/µL Neutrophils > 1500/ µL Platelets > 100,000/µL Hemoglobin > 9.0 g/dL
(may have been transfused) Creatinine < 1.5 mg/dL AST/ALT < 2.5 X ULN for subject
with no liver metastases < 5 X ULN for subjects with liver metastases Bilirubin <
1.5 mg/dL (unless diagnosed with Gilbert's syndrome, who can have total bilirubin
< 3.0 mg/dL) INR or PT < 1.5 X ULN unless the subject is receiving anticoagulant
therapy aPTT or PTT < 1.5 X ULN unless the subject is receiving anticoagulant
therapy

8. Calculate and record creatinine clearance using the Cockcroft-Gault formula.

9. No known positivity for human immunodeficiency virus (HIV) (no laboratory testing
is required), no active infection with Hepatitis B or Hepatitis C.

10. Life expectancy > 12 weeks.

11. Subject Re-enrollment: This study permits the re-enrollment of a subject that has
discontinued the study as a pre-treatment failure (i.e., subject has not been
treated with SX-682) after obtaining agreement from the medical monitor prior to
re-enrolling a subject. If re-enrolled, the subject must be re-consented.

3. Age and Reproductive Status

1. Men and women, ages > 18 years of age.

2. Women of childbearing potential (WOCBP) must use method(s) of contraception (as
will be explained in detail) while on study and for 4 months after the last dose
of SX-682 or pembrolizumab. A WOCBP is defined as any female who has experienced
menarche and who has not undergone surgical sterilization (hysterectomy or
bilateral oophorectomy) or is not postmenopausal. Menopause is defined clinically
as 12 months of amenorrhea in a woman over age 45 in the absence of other
biological or physiological causes.

3. Women under the age of 62 with a history of being postmenopausal must have a
documented serum follicle stimulating hormone, (FSH) level > 40 mIU/mL.

4. Women must have a negative serum or urine pregnancy test (minimum sensitivity 25
IU/L or equivalent units of HCG) within 24 hours prior to the start of study
drug.

5. Women must not be breastfeeding.

6. Men who are sexually active with WOCBP must use any contraceptive method with a
failure rate of less than 1% per year while on study and for a period at least 6
months after the last dose of study drug.

7. Women who are not of childbearing potential and azoospermic men do not require
contraception.

Exclusion Criteria:

1. Target Disease Exceptions

1. Active brain metastases or leptomeningeal metastases are eligible if the treating
physician determines that immediate CNS specific treatment is unlikely to be
required before trial screening/enrollment. Subjects with treated/stable brain
metastases are also eligible. An MRI is not required to rule out brain metastases
or leptomeningeal metastases. There must also be no requirement for high doses of
systemic corticosteroids that could result in immunosuppression (> 10 mg/day
prednisone equivalents) for at least 2 weeks prior to study drug administration.

2. Ocular melanoma is excluded (mucosal melanoma is acceptable).

2. Medical History and Concurrent Diseases

a) Any serious or uncontrolled medical disorder that, in the opinion of the
investigator, may increase the risk associated with study participation or study drug
administration, impair the ability of the subject to receive protocol therapy, or
interfere with the interpretation of study results. Specifically:

1. Subjects with active, non-infectious pneumonitis.

2. Subjects with interstitial lung disease or a history of pneumonitis that required
oral or intravenous glucocorticoids to assist with management.

3. Subjects with clinically significant heart disease that affects normal
activities.

b) Prior malignancy active within the previous 3 years except for locally curable
cancers that have been apparently cured, such as basal or squamous cell skin cancer,
superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.

c) Subjects with active, known or suspected autoimmune disease. Subjects with
vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune
condition only requiring hormone replacement, psoriasis not requiring systemic
treatment, or conditions not expected to recur in the absence of an external trigger
are permitted to enroll.

d) Subjects with a condition requiring systemic treatment with either corticosteroids
(> 10 mg daily prednisone equivalents) or other immunosuppressive medications within
14 days of study drug administration. Inhaled or topical steroids, and adrenal
replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of
active autoimmune disease.

e) Use of other investigational drugs (drugs not marketed for any indication) within
30 days before study drug administration.

f) Use of QT prolonging drugs must be stopped at least two (2) weeks before the start
of SX-682 dosing and suspended for the length of the trial.

g) Subjects who have had major surgery in the past 4 weeks. h) Subjects who have
received a live-virus vaccine within 30 days before study drug administration.

3. Physical and Laboratory Test Findings

1. Any positive test for hepatitis B virus or hepatitis C virus indicating acute or
chronic infection.

2. Known history of testing positive for human immunodeficiency virus (HIV) or known
acquired immunodeficiency syndrome (AIDS).

3. ECG demonstrating a QTc interval >470 msec or patients with congenital long QT
syndrome.

4. Allergies and Adverse Drug Reaction

1. History of allergy to study drug components.

2. History of severe hypersensitivity reaction to any monoclonal antibody

5. Sex and Reproduction Status

1. WOCBP who are pregnant or breastfeeding.

2. Women with a positive serum or urine pregnancy test at enrollment or prior to
administration of study medication.

6. Other Exclusion Criteria

1. Prisoners or subjects who are involuntarily incarcerated, or other vulnerable
populations (study is exempt from 45 CFR 46 Subparts B, C, and D).

2. Subjects who are compulsorily detained for treatment of either a psychiatric or
physical (e.g., infectious disease) illness.